CA2254108C - Improvements in or relating to specific binding assays - Google Patents
Improvements in or relating to specific binding assays Download PDFInfo
- Publication number
- CA2254108C CA2254108C CA002254108A CA2254108A CA2254108C CA 2254108 C CA2254108 C CA 2254108C CA 002254108 A CA002254108 A CA 002254108A CA 2254108 A CA2254108 A CA 2254108A CA 2254108 C CA2254108 C CA 2254108C
- Authority
- CA
- Canada
- Prior art keywords
- analyte
- interest
- solid support
- analogue
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
Abstract
Disclosed is a method of detecting the presence of an analyte of interest in a sample, the method comprising the steps of: contacting the sample with a sol id support having reversibly immobilised thereon either a binding partner havin g specific binding affinity for the analyte, or an analogue of the analyte; an d detecting a reduction in the mass of material immobilised on the solid support, said binding partner or analogue being specifically displaced from the solid support in the presence of the analyte of interest, so as to cause a detectable change in the mass of material immobilised thereon. Also disclose d is a device for performing the method.
Description
Title: Improvements in or Relating to Specific Binding AssUs Field of the Invention This invention relates to a method of detectinQ the presence of an analyte of interest, and an assay device for performing the method.
Background of the Invention Numerous assavs have been described which make use of the specific binding properties of certain molecules to detect the presence of an analyte of interest in a sample. Typically such assavs involve the specific binding between immuno-lobulins (such as antibodies or functional bindina fragments thereof) and haptens or antigens to which the immunoglobulins bind. Examples of such assays include enzyme-linked immunosorbent assays (ELISAs) and radio-immunoassay (RIA).
Conventionally, in order to detect binding between the analvte of interest and a binding partner having specific bindina affinity therefor. it is necessarv for the bindina partner to be labelled. Known labels include enzymes, radio-labels, fluorescent or chemiluminescent labels, electroactive labels (such as redox labels) and coloured particles (e.g. latex beads).
A refinement of assays of the sieneral nature outlined above relates to "displacement"
assays. In such assays, the presence of an analyte of interest in a sample causes the displacement either of a labelled binding partner or a labelled ligand from a pre-existing bindinQ partner/ligand complex. Generallv speaking the amount of displaced labelled substance will be proportional to the concentration of the analyte of interest in the sample.
Alternatively, one may employ "competition" assays, in which there is competition between the analyte of interest and a labelled competitor (such as labelled analyte or analogue) for bindinR to available binding sites.
Background of the Invention Numerous assavs have been described which make use of the specific binding properties of certain molecules to detect the presence of an analyte of interest in a sample. Typically such assavs involve the specific binding between immuno-lobulins (such as antibodies or functional bindina fragments thereof) and haptens or antigens to which the immunoglobulins bind. Examples of such assays include enzyme-linked immunosorbent assays (ELISAs) and radio-immunoassay (RIA).
Conventionally, in order to detect binding between the analvte of interest and a binding partner having specific bindina affinity therefor. it is necessarv for the bindina partner to be labelled. Known labels include enzymes, radio-labels, fluorescent or chemiluminescent labels, electroactive labels (such as redox labels) and coloured particles (e.g. latex beads).
A refinement of assays of the sieneral nature outlined above relates to "displacement"
assays. In such assays, the presence of an analyte of interest in a sample causes the displacement either of a labelled binding partner or a labelled ligand from a pre-existing bindinQ partner/ligand complex. Generallv speaking the amount of displaced labelled substance will be proportional to the concentration of the analyte of interest in the sample.
Alternatively, one may employ "competition" assays, in which there is competition between the analyte of interest and a labelled competitor (such as labelled analyte or analogue) for bindinR to available binding sites.
Several assay methods relying on competition and/or displacement are described in the prior art. For example, EP 0,324,540 discloses assays designed to measure the amount of free ligand (rather than complexed ligand, which complexed ligand is rypically protein-bound) in bioloaical samples such as plasma or serum. The assay method requires the use of a "signal reagent", which is a labelled monoclonal antibody. The monoclonal binds to free ligand, which is in competition with a ligand analogue (which analogue does not bind to the natural ligand complexing proteins present in the sample). Typically the analogue is immobilised (e.g. on particles or beads). The analogue is selected to have a lower affinity than the ligand for the anti-ligand monoclonal antibody. The assay thus works on the principle of immuno-competition, the presence of free ligand in the sample serving to decrease the amount of labelled antibodv which becomes associated with the ligand analogue.
WO 91/05262 discloses a device and method for detecting the presence of molecular analytes in a fluid (especially e.g. steroids, and other low molecular weight analytes).
TypicalIv, aqueous biological samples are drawn along a test strip bv capillarv action. As the sample advances, it carries a labelled analvte from an area of storage at one end of the strip to a first binding means, which is an anti-analyte antibody. In the absence of free analyte in the sample. the labelled analvte (e. Q. analyte/enzvme conjugate) will remain bound to the first bindina means. However, if free analyte is present in the sample it will tend to displace the labelled analyte (or at least. compete therewith for bindinQ sites on the first binding means) such that some labelled analyte will be bound to the second binding means, which is an anti-enzyme antibody. Colour is developed by placing the strip in an appropriate substrate solution.
EP 0,383,313 discloses a composition and assay method "for measurinQ haptens.
antiszens or antibodies bv means of a competitive binding method". The invention disclosed therein requires that either the antibodv or its ligand is labelled.
However, useful as such assays are, the requirement for labelling is disadvantageous.
Radio-labels represent obvious hazards in handling and disposal. Enzyme or other active labels may deteriorate during storaae, affecting the sensitivity of the assav.
Use of coloured particles causes problems in that the relatively lar-ge surface area of the particles introduces non-specific binding sites which can affect the accuracv of the assay.
The present invention seeks to reduce these difficulties by providing an assay method and device which do not require the use of conventionally-labelled reagents.
Summarv of the Invention In one aspect the invention provides a method of detecting the presence of an analyte of interest in a sample, the method comprising: specific displacement from a solid support of a reversibly immobilised binding partner having specific binding affinity for the analyte, or similar specific displacement from a solid support of a reversibly immobilised analogue of the analyte; said displacement occurring in response to the presence of the analyte of interest, and Qiving rise to a detectable signal, characterised in that neither said reversibly immobilised binding partner nor said analogue of the analyte comprises a conventional label.
Generally the method involves the detection of a reduction in the mass of material immobilised on the solid support, as a result of the specific displacement of the binding partner or analogue. In a second aspect the invention provides a method of detecting the presence of an analyte of interest in a sample, the method comprising the steps of:
contacting the sample with a solid support having reversibly irnmobilised thereon either a binding partner having specific binding affinity for the analyte, or an analogue of the analyte; and detecting a reduction in the mass of material imtnobilised on the solid support. said binding partner or analogue being specifically displaced from the solid support in the presence of the analyte of interest, so as to cause a detectable chanQe in the mass of material immobilised thereon.
Changes in the mass of material immobilised on the solid support can cause detectable changes in a number of mass-dependent phenomena which can be detected, for example, by acoustic wave or evanescent wave type sensors or by surface plasmon resonance (SPR) detectors, all of which are known in the art (see. for example, those disclosed in EP 0 341 927, EP 0 416 730 and EP 0 453 224). A particularly suitable mass-dependent phenomenon for detection is the refractive index of the surface of the solid support to which material is immobilised.
In a third aspect the invention provides an assay device for detecting the presence of an analyte of interest in a sample, the device comprising: a solid support having reversibly immobilised thereon either a binding partner having specific binding affinity for the analyte, or an analogue of the analyte; and detection means for detecting a change in the the mass of material immobilised on the solid support. wherein the presence of the analyte of interest in the sample causes specific displacement of the binding partner or analogue from the solid support, so as to cause a detectable change in the mass of material immobilised thereon.
The invention also provides an assay device for detecting the presence of an analyte of interest in a sample, the device comprising a solid support having reversibly immobilised thereon a binding partner having specific bindina affinity for the analyte or having reversibly inunobilised thereon an analogue of the analvte, said bindina partner or analogue not comprising a conventional label and being specifically displaced from the solid support in response to the presence of the analyte of interest. so as to give rise to a detectable signal.
The assay method and device of the invention may be used in a qualitative manner to detect the presence of the analyte of interest. They may also be used in a quantitative manner to measure the amount of analyte present.
In many embodiments the displaced binding partner or analogue of the analyte desirably do not comprise (nor are complexed with, conjugated or in any way linked to) any label whatsoever. However, in certain embodiments, as explained below, it is desirable for the displaced binding partner or analogue to comprise a non-conventional label.
The term "conventional label" as used herein refers to labels such as enzymes, radio-labels, fluorescent or chemiluminescent labels, electroactive labels (such as redox labels), and coloured particles (such as latex, or coloured or metallic sols). All of the foregoing labels are primarily detectable in some way other than by simply detecting the mass of the label substance. In the present invention, the non-conventional label relies solely on its mass to give rise to a detectable signal.
In most preferred embodiments of the present invention displacement of the binding partner or analogue of the analyte is an event which is directly detected (e.g. typically by use of an evanescent or acoustic wave-type or SPR sensor) and so gives rise to a signal.
It will be appreciated that in the method/device of the invention the signal is essentially generated at the site of displacement of the binding partner or analogue, rather than being "stored" in some labelled entity.
The binding partner and the analyte are conveniently members of a specific binding pair..
Numerous examples of such specific binding pairs are known (e.g. DNA and DNA-binding proteins, hormones and their receptors, antigens and antibodies thereto).
Typicallv the binding partner is a protein, preferably an immunoglobulin (e.g.
antibody) or a functional binding fragment thereof, which term relates to, inter alia, Fv, scFv, Fab, Fab, and the like. In certain preferred embodiments the binding partner is a protein having specific binding activities for two distinct ligands. Examples of such proteins are bispecific antibodies or "Diabodies", which are well known to those skilled in the art.
The reversibly immobilised binding partner or analyte analogue mav be bound to the solid support in any one of a number of ways, which will be apparent to the person skilled in the art. The binding partner or analyte analogue may normally be removed from the solid support by application of particular chemicals (e.g. solutions. such as 50mM
glycine, buffered to very low [= pH2] or 50mNI diethylamine buffered to very high pH [=
pH 12]
and the like) but, under conditions in which the assay is performed (such as those generallv found in biological svstems), will be released from the solid support only by the presence of the analyte of interest. Typically the sample assayed will be a biological sample (such as a body fluid e.g. urine, whole blood or serum), and the assay conditions will be broadly physiological (e.g. about 10-40 C, about pH 5-9). such that the binding partner or analyte analogue will only be released from the solid support by the presence of the analyte of interest.
The assay method of the invention may be performed. or the assay device used, in any one of several different formats. For example, the reversibly immobilised binding partner may be an immunoglobulin, bound to a solid support via interaction with an antigen, which is the analyte of interest. The presence in the sample of high concentrations of the free antigen will tend to cause displacement of the immunoglobulin from the solid support.
Such an assay will generally be effective only when there is a high concentration of free analyte of interest in the sample.
Conveniently. in one embodiment, an analogue of the analyte of interest is immobilised (via covalent interactions) on a solid support. Methods suitable for accomplishing this are well known to those skilled in the art. A bindin(z partner specific for the analvte is then allowed to bind (comparatively loosely) to the analo-aue of the analyte (e.g.
via non-covalent interactions), so as to reversibly inunobilise the binding partner to the solid support. A preferred embodiment of the invention therefore has an immunoglobulin bound to a solid support via a non-covalent interaction with an analogue of the analyte of interest (the analogue typically being covalently bound to the solid support), the immunoalobulin having a lower affuiity for the analogue than for the analyte. Accordingly.
the presence of the analyte of interest in the sample, even at low concentrations, will tend to cause displacement of the immunoglobulin. Desirably. the binding affinity of the immunoglobulin for the analyte of interest is between 5 and 100 times areater than its affinity for the analogue, typically between 10 and 20 times greater.
For reasons which will become apparent, the method/device of the invention finds particular advantage when applied to the detection of relatively low molecular weight analytes (e.g. steroids and the like) having molecular weights of around RD or less. One such analyte is the steroid estradiol, or metabolites thereof such as estrone-3-2lucuronide.
Thus. for example. where the analyte of interest is estrone-3-alucuronide, a suitable analoeue thereof for use in detecting the presence of the analyte in accordance with the invention may be estriol-3-glucuronide. Other possibly suitable anaiogues will be apparent to those skilled in the art and include. for example, estrone, estrone-3-sulphate, estriol, estradiol and estradiol-3-glucuronide.
In an alternative embodiment, the assay method of the invention may involve displacement not of a binding partner of the analyte, but of an analogue of the analyte.
For example, an immunoglobulin mav be immobilised on a solid support in such a way that at least one antigen binding site is available for binding antigen. Typically, prior to performance of the assav, substantially all of the available binding sites are occupied by an analogue of the analyte of interest, the immunoglobulin having a lower binding affinity for the analogue than for the analvte of interest such that, upon addition of a sample containing the analvte of interest, the analogue will he displaced from the binding site of the immunoglobulin.
The immunoglobulin (e.g. IgM) could have a pluralitv of binding sites such that one binding site interacts with antigen bound to a solid support, leavinQ another free to be occupied bv analvte analogue prior to assav. Alternativelv, the antibody could possess a single binding site (like Fv or Fab fragments of Ig) but be immobilised to a solid support in such a wav that the single binding site is available for occupation.
Immunoglobulin molecules (such as IgG) may conveniently be immobilised via an anti-Fc antibody, as described in Example 2 below.
Thus, in one embodiment, an anti-Fc antibody is immobilised (typically via a covalent interaction) upon a solid support. A second antibody, specific for the analyte of interest, is then captured on the solid support by the anti-Fc antibody. The binding sites of the analyte-specific antibody are then substantially fully occupied by an analogue of the analyte of interest, such that the analogue is reversibly immobilised upon the solid support via non-covalent interaction with the analyte-specific antibody. The affinity of the analyte-specific antibodv for the analyte of interest is desirably between 5 and 100 times greater than its affinity for the analogue.
Conveniently, the solid support comprises part of a biosensor device. A
biosensor may be defined as an analytical device which comprises a biological molecular recognition component, which device typically produces an electronic signal dependent on the presence and/or concentration of an analyte interacting with the biological recognition component.
AMENDED SHEET
Such biosensor devices are well-known and are described, for example, in EP 0 341 927, EP 0 416 730 and EP 0 453 224. Preferably the biosensor detects a change in a mass-dependent property of the solid support (e.g. speed of propagation of an acoustic wave, propagation of an evanescent wave, or surface plasmon resonance). Examples of such devices which utilise the evanescent wave or SPR phenomena (Hutchinson 1995 Molecular Biotechnology 3, 47-54 and references therein) include the BIAIiteTM and BIAcoreTM
devices sold by Biacore AB, the IAsysTM device sold by Affinity Sensors Limited (UK), and the BIOS-1 device sold by Artificial Sensor Instruments (Zurich, Switzerland).
Displacement of antibody molecules from the sensor surfaces of such devices causes a relatively large decrease in mass, which is readily detectable. However, in those embodiments where an analogue of the analyte of interest is displaced by the analyte, it will be apparent to those skilled in the art that, for evanescent wave-type sensors and other mass-dependent biosensors, the analogue must have a sufficientlv hiaher molecular weight than the analyte, otherwise the net change in mass may be very small and thus difficult to detect.
For example, where the analyte is a low molecular weight compound. such as a steroid or a peptide, the analogue may be conjugated to a high molecular weight substance so as to create a higher molecular weiQht difference between the analvte and the analogue. High molecular weiaht substances suitable for conjugation include proteins such as ovalbumin or bovine serum albumin (BSA), or other entities such as lipids and the like.
It is to be noted that these substances are not conventional labels such as enzymes, radiolabels, fluorescent or chemiluminescent tags, redox labels or coloured particles and the like, but serve merely to create a disparity in molecular weiaht between the analyte and the analogue.
Alternatively, where the analogue is a peptide. the molecular weiaht of the analogue may be increased relative to the analyte, by using the peptide as part of a fusion protein.
Conveniently the peptide may be fused to the N-terminal or, more preferably, the C-terminal of a polypeptide. Methods for the construction of DNA sequences encoding such fusion proteins are well known to those skilled in the art.
The added molecular mass represented by the polypeptide may be viewed as a non-conventional label. However, the fused or, as may be the case conjugated, polypeptide need not retain any particular activity unlike, say, an enzyme label, so that the assay component will not become less sensitive due to loss of activitv durinQ
storage. Similarly, the use of a single polypeptide rather than a comparatively larae latex bead (as in the prior art) will introduce comparatively few non-specific binding sites, such that the accuracy of the assav will not be adversely affected.
Brief Description of the Figures Fizure 1 shows the structural formulae of the compounds (I) estrone 3-D-glucuronide (abbreviated as estrone-3-glucuronide or E3G) and (II) estriol 3-(0-D-alucuronide) (abbreviated as estriol-3-aiucuronide), which compounds are utilised in Example 1 below;
Figure 2 is a schematic representation of the assay format described in Example 1 below;
Figure 3 is a sensorgram (arbitary Resonance Units, "RUs". against time measured in seconds) showing the preparation of an estriol-3-~lucuronide sensor chip;
Figure 4 is a(zraph of Resonance Units against time (seconds). showing displacement of 4155 antibodv bv estrone-3-alucuronide:
Figure 5 is a;raph of amount of 4155 antibody displaced (RUs) aQainst concentration of estrone-3-jlucuronide (nM):
Figttre 6 is a schematic representation of the assay format desribed in Example 2 below;
Figure 7 is a sensorgram (arbitary Resonance Units aQainst time, in seconds) showing the preparation of a Rabbit anti-mouse (RAM) Fc sensor chip;
Figure 8 is a sensorgram (Resonance Units against time, in seconds) showing binding of anti-human milk fat globulin HMFG I antibody to a RAM Fc sensor chip, and binding of CPDTR peptide-conjugate to the HMFG1 antibody; and Figure 9 is a sensorgram (Resonance Units against time, in seconds) showing displacement of CPDTR peptide-conjugate from HMFG1 antibody by KPDQR peptide.
Examples Example 1 In this example an assay is described which utilises surface plasmon resonance (SPR).
This phenomenon has now been described in several publications and is the basis of evanescent wave biosensors (for a review, see Hutchinson 1995 cited above).
In summary, lioht incident on an interface between two media of different refractive indices will, at a specific angle of incidence, generate a resonant "evanescent" wave. The resonance is extremely sensitive to chancres in the refractive index of the media. A change in the refractive index causes resonance to occur at a new angle of incidence.
The change in refractive index is caused bv mass binding to a thin gold film at the interface between the two media: the chanQe in refractive index is proportional to the mass bound to the gold film.
This example concerns an assay for the detection of estrone-3-glucuronide (a steroid hormone metabolite) and involves use of an analogue thereof, estriol-3-2lucuronide.
Details of the structures of these compounds are shown in Figure 1.
Further by way of information this example makes use of the Pharmacia BIAIiteTM
evanescent wave biosensor (Jonsson et al., 1991 BioTechniques II, 620-627).
Figure 2 schematicallv illustrates the assay method. In step "A". an analoaue (estriol-3-Qlucuronide, denoted in Figure 2 bv a solid circle) of the analyte of interest (estrone-3-glucuronide denoted bv a solid triangle) was covalently immobilised on the activated dextran-coated surface of a solid support (a sensor chip of the Pharmacia BIAliteTM
biosensor). In step "B", antibodv (monoclona14155, denoted by the Y shape) specific for estrone-3-glucuronide was then allowed to bind to the immobilised analogue.
The antibody has comparatively low binding affinity for the analogue, such that the antibody is relatively loosely held (reversibly immobilised) on the biosensor chip.
Introduction of a sample containing the analyte of interest (for which the antibody has comparatively high binding affinity) will therefore cause the antibody to bind preferentially to the analyte (step "C") rather than to the immobilised analogue, so causing displacement of the antibody from the sensor chip, which displacement can be readily detected by the sensor device.
As a first step, estriol-3-glucuronide was immobilised on a sensor chip in the BIAIiteTM
biosensor. The method of immobilisation was essentially as described by Johnsson et al.
(1995 J. Molec. Recognition 8, 125-131) and by O'Shanessy et al. (1992 Analytical Biochemistry 205, 132-136). In summary, the process was as follows:-A CM5 sensor chip was docked in to the BialiteT" instrument and equilibrated in the HBS
running buffer. The instrument pump flow rate was set to 5 1/min and temperature was maintained at 25 C.
The dextran surface was then activated using the 1-ethyl(dimethvlaminopropyl)carbodiimide (EDC) and N-hvdroxvsuccinimide (NHS) activating chemicals from the Pharmacia amine coupling kit bv injecting the EDC/NHS
mixture into the sample loop and loading 35,ul over the dextran surface.
EDC/NHS
activation can be seen at position (1) on the sensorgram in Figure 3.
After the surface was activated by EDC/NHS 20% (v/v), ethylene diamine (EDA) (Fluka, Code 03550) in water was injected into the sample loop. 35 1 of this solution was loaded over the surface. This changes the surface groups from carboxvl to amine derivatised.
This can be seen at position (2) on the sensorgram in Figure 3.
Estriol-3-Qlucuronide (Sigma. Code E-2002) was dissolved at l.lmg/mi concentration in EDC/NHS activation mixture and left to react for 7 minutes. This solution was then injected into the sarnple loop and 57 1 of this solution was loaded over the dextran/EDA
surface. This can be seen at position (3) on the sensorgram in Figure 3.
The sensor chip was then washed with HEPES-buffered saline (HBS).
The assay was performed as follows:-i) The estriol-3-glucuronide sensor chip was docked in the BIAliteT"
instrument and equilibrated with HBS running buffer. The temperature was maintained at 25 C
and pump flow rate kept at 5 l/min.
ii) Mouse monoclonal antibody specific for estrone-3-glucuronide (produced bvi cell line "4155 ") was diluted to 30 g/ml in HBS buffer. This solution was injected into the sample loop and 35 1 was loaded over the biosensor chip surface. The 4155 monoclonal cell line was prepared and screened accordinLy to the methods described by Gani et al.,(1994 J.
Steroid Biochem. Molec. Biol. 48, 277-282). The Gani et al. publication relates to development of anti-progesterone antibodies, but essentially identical techniques were emploved in producing antibodies reacting with estrone and analogues thereof.
Antibodies other than that obtainable from cell line 4155 may readily be produced by those skilled in the art (using such techniques): such antibodies would have qualitativelv similar properties.
Moreover, a commerciallv available anti-estrone alucuronide monoclonal antibody (from Wallaceville Animal Research Centre. New Zealand) is described in Linscott's Directory of Immunological and Bioloaical Reagents (9th edition, 1996-7).
iii) Estrone-3-alucuronide (Sigma product code E1752) was dissolved in HBS
buffer at 1mg/ml. This was diluted further to 20.5nM, 2.05nM and 0.205nM concentrations with HBS buffer respectively. The concenrations used represent the physiological concentrations of E3G found in urine (Stancyzk et al., 1930 Am. J. Obs. &
Gynae.
137(4), 443-450). The 20.5nM E3G solution was injected into the sample loop and 35 i was loaded over the biosensor chip surface to displace the bound 4155 antibody.
iv) After the injection was complete the remaining antibodv was removed usina a 1041 loadin2 of 100mM HCl over the biosensor chip surface.
v) Steps (ii) to (iv) were repeated using the estrone-3-glucuronide dilutions at 2.05nM
and 0.205nM respectively.
Preparation of sensor chip The sensorgram for the immobilisation of the sensor chip is shown in Figure 3.
The steroid coupled to the surface cannot be detected by looking at the sensorgram trace and comparing the baseline before immobilisation and after immobilisation. This is because the estriol-3--lucuronide molecular weight is below the limit of detection for the BIAIiteTM.
Investi2ation of the displacement reaction with the estriol-3-alucuronide sensor chip The 4155 antibodv was able to bind in large amounts to the estriol-3-glucuronide that had been covalently linked to the sensor chip. The 4155 antibody was displaced from the surface of the chip upon injection of the estrone-3-glucuronide. The amount of antibody displaced by the estrone-3-glucuronide was dependant on the steroid concentration (see Figure 4: the solid line shows results using 0.2nM E3G, the dashed line shows results obtained with 2.OnM E3G, the dashed line shows results obtained with 2.0nM
E3G, and the dotted line shows results obtained with 2.OnM E3G, and the dotted line shows results obtained using 20nM E3G). To show this was a linear correlation a graph (Figure 5) was drawn plotting steroid concentration against (i) the amount of antibody displaced in RUs (left hand vertical axis) and (ii) the % of antibody displaced compared to the amount bound to the surface (right hand vertical axis).
The concentrations of estrone-3-glucuronide (E3G) used in the experiment span the physiological range of E3G concentrations found in human urine samples. In the displacement experiment, it is clearly seen that the amount of antibody displaced by the E3G steroid is directly proportional to the concentration of the E3G (see Figure 5).
This displacement reaction demonstrates the possibility of ineasuring small molecular liaands with the biosensor that themselves are below the minimum threshold for detection by surface plasmon resonance with the BIAIiteTM instrument. The displacement reaction can form the basis of new immunoassay formats that requires no labelling of reagents with enzymes or radioactive molecules. All that is required for this type of assay to work is a low affinity antigen analogue that can be immobilised to the dextran.
Example 2 Displacement of crossreactive svnthetic peptide ovalbumin conjuQates from antibody A schematic illustration of this displacement reaction can be seen in Figure 6.
Referring to Figure 6, the solid support is the sensor chip of the Pharmacia BIA1iteTM
biosensor, coated with activated dextran. A first antibody (polyclonal rabbit anti-mouse immunogiobulin G["RAM"] specific for the Fc portion of IgG), was covalently immobilised to the activated dextran ("A"). Next, a second (mouse) antibody, specific for the analyte of interest, is added ("B"). The analvte of interest in this example is a peptide (KPDQR) derived from human milk fat globulin (HMFG)1 protein. The anti-HMFG1 monoclonal antibody is described by Taylor-Papadimitriou et al (1981 Int. J.
Cancer 28, 17). The anti-HMFG1 monoclonal antibody is captured on the sensor chip by the RAM
first antibodv. The first and second antibody molecules are shown in FiQure bv the Y
shapes.
Next an analogue (peptide CPDTR using the single letter amino acid code) of the peptide analyte of interest was introduced. In this example, both the analyte and the analogue are low molecular weight peptides, which cannot readily be distinguished by differences in molecular weight. Accordingly, a high molecular weight polypeptide (ovalbumin) was chemically conjugated to the peptide analogue. This peptide-ovalbumin conjuoate (shown in Figure 6 as a solid oval shape) was bound with relatively low affinity by the anti-HMFG1 antibody, such that the analogue was reversibly immobilised on the solid support (C). When the peptide analyte of interest (KPDQR, shown in Figure 6 as a solid triangle) was introduced, the anti-HMFG1 tended to bind preferentially thereto (having a higher affinity for the analyte of interest than for the analogue). Accordingly ("D") the analyte became bound to the sensor chip and the higher molecular weight analogue -ovalbumin conjugate was displaced. The change in mass bound to the sensor chip can be detected by the BIAIite" device.
a) Preparation of polvclonal rabbit anti-mouse immunoQlobulin G (Fc specific) sensor chin i) A carboxy methyl dextran (CM5) sensor chip (Pharmacia. Code BR-1000-14) was docked in to the BIA1iteT't instrument and equilibrated in the HEPES buffered saline (HBS) (Pharmacia, Code BR-1001-88). The instrument pump flow rate was set to 5 l/min and temperature was maintained at 25 C.
ii) The dextran surface was then activated using the EDC and NHS activatinsz chemicals from the amine coupling kit (Pharmacia, Code BR-1000-50). EDC/NHS mixture was injected into the sample loop and 35 1 of this solution loaded over the dextran surface.
EDC/NHS activation can be seen at position (1) on the sensorgram in Figure 7.
iii) Polvclonal rabbit anti-mouse immunoglobulin G (Fc specific) (RAM Fc) (Pharmacia.
code BR-1000-57) was diluted down to 50 g/ml in 10mM acetate buffer pH5.0 and injected into the sample loop. 35 1 of this solution was loaded over the dextran surface.
The coupling of the RAM Fc to the dextran can be seen at position (2) on the sensorgram in Figure 7.
iv) Once the RAM Fc loading was complete and unbound RAM Fc washed from the dextran surface by HBS running buffer, the remaining activated ester sites on the dextran surface were reacted with ethanolamine. 1M ethanolamine pH8.5 (Pharmacia amine coupling kit. Code BR-1000-50) was injected in to the sample loop and 3541 loaded over the dextran/RAIVI Fc surface. This can be seen at position (3) on the sensorgram in Figure 7.
v) To remove any non-covalentlv attached RA..M Fc from the surface 100mM HCI
was injected in to the sample loop and lOul of this solution was loaded over the dextran/RA.M
Fc surface. This can be seen at position (4) on the sensorgram in Figure 7.
b) Preparation ot svnthetic peptides Cvs-Pro-Asp-Thr-Ara (CPDTR) and Lvs-Pro-As]2-Gln-Aro (hPDOR) for the displacement reaction The peptides used here were modified variants of the natural epitope Pro-Asp-Thr-Arg (PDTR) sequence in the human milk fat globulin 1 protein to which the antibody anti-HMFG1 binds (Bri(y,s et al., 1991 Immunology 73, 505-507). The Cys (C) in CPDTR
was added to allow the peptide to be coupled to commercially available maleimide activated ovalbumin and create a useful conjugate. This conjugate is required since the peptide alone does not have sufficient mass to be detected by the BIAIiteTM
instrument.
There is a threshold of about 5000 daltons of mass required before molecules will register with the BIAlite" instrument.
Whilst the work described in this example relates to experiments performed with the monoclonal antibody HMFG1, other antibodies having qualitatively similar properties may readily be produced by those skilled in the art. Moreover, a commercially available anti-milk fat globulin monoclonal antibody (from Paesel & Lorei GmbH, Hanau.
Germany) is described in Linscott's Directorv of Immunological and Biological Reagents (9th edition, 1996-7).
In the work done to identify the critical aminoacid residues within the HMFGI
epitope (Price et al., 1991 J. Immunological Methods 139, 83-90) a number of variants were created that had affinities differine from the native PDTR sequence. Pro-Asp-Gln-Arg (PDQR) is an analogue of the PDTR sequence that has a higher affinitv for the antibody than PDTR. The peptide KPDQR was synthesised with an N-terminal lysine to improve the soluhility of the peptide. However, as this peptide contained the PDQR
sequence it was also suitable for investigating the immunodisplacement reaction. The N-terminal lysine could be readily omitted without substantial deleterious effect.
AMENDED SHEET
i) Peptides were synthesised on a Novabiochem GEM semi-automatic synthesizer, using standard techniques as previously published (Merrifield, 1963 J. Am. Chem.
Soc. 85, 2149-2154). Briefly, Fmoc-aminoacid reagents (Novabiochem) were activated sequentially using PyBOP chemistry (Grant, 1992 "Synthetic peptides. A user's guide" pub. W
H
Freeman & Co New York). These activated aminoacids were coupled to the solid support Novasyn TGR resin (0.8g) (Novabiochem) to produce the protected peptide attached to a solid matrix. Dimethylformamide (DMF) solvent was used throughout the synthesis. The peptides were reacted with acetic anhydride (10% in DMF) to block the N-tetmini.
ii) The peptide was then deprotected and cleaved using standard cleavage conditions with 20m1 of cleavage solution per peptide [92.5 % (v/v) Trifluoroacetic acid (TFA) (Aldrich), 2.5% (v/v) Ethanedithiol (Aldrich). 2.5 %(v/v) water, 2.5 %(v/v) triisopropylsilane (Aldrich)]. The solution was filtered to remove the resin and rotary evaporated under vacuum at 30 C with cold finger (dry ice/acetone) trap to remove all excess solvents.
This procedure took 30 minutes.
iii) Residual chemical contaminants were removed by precipitating the peptide with diethyl ether (Aldrich) and repeated extraction of this precipitate with excess diethyl ether.
iv) The peptide precipitate was then solubilised with water and freeze dried.
The resultin2 powder was stored at -20 C until required.
c) Preparation of the CPDTR peptide ovalbumin conjugate Peptide was dissolved in phosphate buffered saline (PBS) to a concentration of 5mg/ml and mixed with 5 milligrams of preactivated maleimide ovalbumin (Pierce) dissolved in lml of PBS. This mixture was left to react at room temperature for 2.5 hours. The excess peptide was then removed by dialysing the sample against 5L of PBS + 0.1 %
sodium azide (Sigma,) for 16 hours at 4 C.
The conjugate was then removed from dialysis and stored at 4 C until required.
d) Displacement of the CPDTR pentide-ovalbumin coniueate from monoclonal HMFGl antibodv with KPDOR peptide The polyclonal rabbit anti-mouse antibody (Fc specific) biosensor chip was placed into the BIAIiteTM instrument and the docking procedure executed. The HEPES buffered saline (HBS) running buffer (Pharmacia product code BR-1001-88) flow rate was then set at 1/min.
A typical sensorgram for the preparation of the RAM Fc sensor chip is shown in Figure 7. Referring to Figure 7. 1 represents the EDC/NHS activation of the dextran surface, 2 represents the RAM Fc coupling to the activated dextran, 3 represents blocking of residual activated dextran sites with ethanolamine, and 4 represents a 100mM
HCI pulse to remove non-covalently bound substances.
Mouse monoclonal antibody specific for human milk fat globulin 1 was diluted to 50)cg/ml in HBS buffer and 35 1 of this solution was injected in to the biosensor chip.
After injection the biosensor chip was automatically washed and 1040 RU of the mouse specific antibody had been bound by the polyclonal rabbit anti-mouse antibody (Fc specific) antibody.
The CPDTR-ovalbumin conjugate was diluted tenfold with HBS buffer and 351A1 of this solution was injected into the biosensor chip. Approximately 204 resonance units were bound by the mouse HMFG1 specific antibody. Peptide KPDQR was dissolved to 200 g/ml in HBS buffer and 35 1 of this solution was injected into the biosensor chip to displace the CPDTR-ovalbumin conjugate.
The residual bound CPDTR-peptide conjugate and mouse anti-HMFG1 were then removed by washing the sensor chip briefly with 100mM HCI.
A control experiment was performed in an identical manner except no peptide Lys-Pro-Asp-Gln-Arg was injected.
Results Preparation of RAM Fc sensor chip The coupling of the sensor chip resulted in a high capacity RAM Fc specific sensor chip that had approx 8000 RU of RAM Fc immobilised at the end of the procedure (see Figure 7). The RAM Fc binds the mouse HMFG1 antibody with multiple binding sites for each antibody molecule, thus giving a high avidity for the molecule. The effect of the high avidity is negligible dissociation of the monoclonal antibody from the RAM Fc layer.
This can be seen at position 2 in Figure 8 where there is almost a flat line for the dissociation of HMFG1 from RAM Fc. This condition is required in order to ensure that any loss of RUs in the displacement experiment is due to immunospecific displacement of CPDTR-ovalbumin by the KPDQR peptide, and not the HMFGI monoclonal antibody dissociating from the RAM Fc layer.
In Figure 8, (1) represents HMFG1 binding to the RAM Fc sensor chip, (2) represents dissociation of HMFG1 antibody from RAM Fc layer, (3) represents CPDTR-ovalbumin conjugate binding to HMFG1 antibody, and (4) represents dissociation of CPDTR-ovalbumin conjugate from HMFG1 antibody.
The SPR signal from molecular binding events is reduced by the mass of the molecule and the distance the event occurs from the resonating gold layer. Molecular interaction studies that require several layers of molecules to be assembled have to compensate for the reductions in signals that occur as each layer of molecules is added and the distance from the gold layer increased. Compensating for this problem is achieved by inunobilising large amounts of ligand in the first layer of the test system. This overcomes the signal reductions and the final molecular binding events are easily observed.
The RAM Fc sensor chip was capable of binding 1000 RU of mouse monoclonal HMFGI
antibody. This was sufficient to ensure that binding of the CPDTR-ovalbumin peptide conjugate to HMFG1 antibody and any displacement effect by peptide KPDQR on the CPDTR-ovalbumin conjugate bound to HMFG1 antibody would be easily observed (see Figure 8).
Displacement of CPDTR-ovalbumin coniuQate from HMFG1 antibodv bv peptide KPDOR
In order to observe whether there had been any displacement of the CPDTR-ovalbumin by the peptide KPDQR, the raw data were analysed in the BIAevaluation package.
Essentially, the two regions of data for the binding of CPDTR-ovalbumin conjugate to HMFG1 antibody with and without the following peptide displacement were plotted as separate graphs and overlaid. To keep the data synchronised the graphs were both aligned at the point of injection for the CPDTR-ovalbumin conjugate (see Figure 9).
The curve with no peptide injected (solid line in Figure 9) shows the normal dissociation of the CPDTR-ovalbumin conjugate from the HMFGI antibody. This is essentially the baseline from which the immunospecific displacement is measured.
The curve with peptide added (broken line in Figure 9) shows the immunodisplacement.
Immediately after the peptide KPDQR injection (denoted by a downward vertical arrow in the Figure) starts there is a sharp rise in the resonance unit signal. This is due to the change from instrument HBS running buffer to the KPDQR peptide buffer and is called "bulk refractive index change".(Bulk refractive index changes occur when samples with buffer composition different from the HBS running buffer of the instrument are injected over the sensor chip. The difference in the ionic strength of the HBS and sample buffers results in a change in the refractive index where the evanescent wave is probing the dextran layer. The refractive index change gives an immediate shift in resonance signal which is observed on the sensorgram.) This increase in resonance units caused by the bulk refractive index change is rapidly lost because immunodisplacement of the CPDTR-ovalbumin conjugate from the HMFG1 antibodv is occurrina, and the loss of mass due to this displacement causes a drop in the resonance signal. Eventually the signal curve flattens because the peptide has removed all the CPDTR-ovalbumin conjugate possible and all that remains is multiply bound CPTDR-ovalbumin conjugate which has such high avidity that it cannot be displaced. At the end of the peptide injection there is an immediate drop in the resonance unit signal that is caused by the switch from sample buffer to the HBS instrument running buffer. A
comparison of the curves with and without peptide injected, i.e.
immunodisplacement versus normal dissociation. shows that there is an additional loss of 100 RU
of CPDTR-ovalbumin conjugate from the HMFG 1 antibody caused by the KPDQR peptide (indicated by the double-headed vertical arrow in Figure 9).
From the data presented in these examples one can see how the invention can be used with particular advantage to assay low molecular weight analytes, such as steroids or peptides, without the need to label any of the assay components.
WO 91/05262 discloses a device and method for detecting the presence of molecular analytes in a fluid (especially e.g. steroids, and other low molecular weight analytes).
TypicalIv, aqueous biological samples are drawn along a test strip bv capillarv action. As the sample advances, it carries a labelled analvte from an area of storage at one end of the strip to a first binding means, which is an anti-analyte antibody. In the absence of free analyte in the sample. the labelled analvte (e. Q. analyte/enzvme conjugate) will remain bound to the first bindina means. However, if free analyte is present in the sample it will tend to displace the labelled analyte (or at least. compete therewith for bindinQ sites on the first binding means) such that some labelled analyte will be bound to the second binding means, which is an anti-enzyme antibody. Colour is developed by placing the strip in an appropriate substrate solution.
EP 0,383,313 discloses a composition and assay method "for measurinQ haptens.
antiszens or antibodies bv means of a competitive binding method". The invention disclosed therein requires that either the antibodv or its ligand is labelled.
However, useful as such assays are, the requirement for labelling is disadvantageous.
Radio-labels represent obvious hazards in handling and disposal. Enzyme or other active labels may deteriorate during storaae, affecting the sensitivity of the assav.
Use of coloured particles causes problems in that the relatively lar-ge surface area of the particles introduces non-specific binding sites which can affect the accuracv of the assay.
The present invention seeks to reduce these difficulties by providing an assay method and device which do not require the use of conventionally-labelled reagents.
Summarv of the Invention In one aspect the invention provides a method of detecting the presence of an analyte of interest in a sample, the method comprising: specific displacement from a solid support of a reversibly immobilised binding partner having specific binding affinity for the analyte, or similar specific displacement from a solid support of a reversibly immobilised analogue of the analyte; said displacement occurring in response to the presence of the analyte of interest, and Qiving rise to a detectable signal, characterised in that neither said reversibly immobilised binding partner nor said analogue of the analyte comprises a conventional label.
Generally the method involves the detection of a reduction in the mass of material immobilised on the solid support, as a result of the specific displacement of the binding partner or analogue. In a second aspect the invention provides a method of detecting the presence of an analyte of interest in a sample, the method comprising the steps of:
contacting the sample with a solid support having reversibly irnmobilised thereon either a binding partner having specific binding affinity for the analyte, or an analogue of the analyte; and detecting a reduction in the mass of material imtnobilised on the solid support. said binding partner or analogue being specifically displaced from the solid support in the presence of the analyte of interest, so as to cause a detectable chanQe in the mass of material immobilised thereon.
Changes in the mass of material immobilised on the solid support can cause detectable changes in a number of mass-dependent phenomena which can be detected, for example, by acoustic wave or evanescent wave type sensors or by surface plasmon resonance (SPR) detectors, all of which are known in the art (see. for example, those disclosed in EP 0 341 927, EP 0 416 730 and EP 0 453 224). A particularly suitable mass-dependent phenomenon for detection is the refractive index of the surface of the solid support to which material is immobilised.
In a third aspect the invention provides an assay device for detecting the presence of an analyte of interest in a sample, the device comprising: a solid support having reversibly immobilised thereon either a binding partner having specific binding affinity for the analyte, or an analogue of the analyte; and detection means for detecting a change in the the mass of material immobilised on the solid support. wherein the presence of the analyte of interest in the sample causes specific displacement of the binding partner or analogue from the solid support, so as to cause a detectable change in the mass of material immobilised thereon.
The invention also provides an assay device for detecting the presence of an analyte of interest in a sample, the device comprising a solid support having reversibly immobilised thereon a binding partner having specific bindina affinity for the analyte or having reversibly inunobilised thereon an analogue of the analvte, said bindina partner or analogue not comprising a conventional label and being specifically displaced from the solid support in response to the presence of the analyte of interest. so as to give rise to a detectable signal.
The assay method and device of the invention may be used in a qualitative manner to detect the presence of the analyte of interest. They may also be used in a quantitative manner to measure the amount of analyte present.
In many embodiments the displaced binding partner or analogue of the analyte desirably do not comprise (nor are complexed with, conjugated or in any way linked to) any label whatsoever. However, in certain embodiments, as explained below, it is desirable for the displaced binding partner or analogue to comprise a non-conventional label.
The term "conventional label" as used herein refers to labels such as enzymes, radio-labels, fluorescent or chemiluminescent labels, electroactive labels (such as redox labels), and coloured particles (such as latex, or coloured or metallic sols). All of the foregoing labels are primarily detectable in some way other than by simply detecting the mass of the label substance. In the present invention, the non-conventional label relies solely on its mass to give rise to a detectable signal.
In most preferred embodiments of the present invention displacement of the binding partner or analogue of the analyte is an event which is directly detected (e.g. typically by use of an evanescent or acoustic wave-type or SPR sensor) and so gives rise to a signal.
It will be appreciated that in the method/device of the invention the signal is essentially generated at the site of displacement of the binding partner or analogue, rather than being "stored" in some labelled entity.
The binding partner and the analyte are conveniently members of a specific binding pair..
Numerous examples of such specific binding pairs are known (e.g. DNA and DNA-binding proteins, hormones and their receptors, antigens and antibodies thereto).
Typicallv the binding partner is a protein, preferably an immunoglobulin (e.g.
antibody) or a functional binding fragment thereof, which term relates to, inter alia, Fv, scFv, Fab, Fab, and the like. In certain preferred embodiments the binding partner is a protein having specific binding activities for two distinct ligands. Examples of such proteins are bispecific antibodies or "Diabodies", which are well known to those skilled in the art.
The reversibly immobilised binding partner or analyte analogue mav be bound to the solid support in any one of a number of ways, which will be apparent to the person skilled in the art. The binding partner or analyte analogue may normally be removed from the solid support by application of particular chemicals (e.g. solutions. such as 50mM
glycine, buffered to very low [= pH2] or 50mNI diethylamine buffered to very high pH [=
pH 12]
and the like) but, under conditions in which the assay is performed (such as those generallv found in biological svstems), will be released from the solid support only by the presence of the analyte of interest. Typically the sample assayed will be a biological sample (such as a body fluid e.g. urine, whole blood or serum), and the assay conditions will be broadly physiological (e.g. about 10-40 C, about pH 5-9). such that the binding partner or analyte analogue will only be released from the solid support by the presence of the analyte of interest.
The assay method of the invention may be performed. or the assay device used, in any one of several different formats. For example, the reversibly immobilised binding partner may be an immunoglobulin, bound to a solid support via interaction with an antigen, which is the analyte of interest. The presence in the sample of high concentrations of the free antigen will tend to cause displacement of the immunoglobulin from the solid support.
Such an assay will generally be effective only when there is a high concentration of free analyte of interest in the sample.
Conveniently. in one embodiment, an analogue of the analyte of interest is immobilised (via covalent interactions) on a solid support. Methods suitable for accomplishing this are well known to those skilled in the art. A bindin(z partner specific for the analvte is then allowed to bind (comparatively loosely) to the analo-aue of the analyte (e.g.
via non-covalent interactions), so as to reversibly inunobilise the binding partner to the solid support. A preferred embodiment of the invention therefore has an immunoglobulin bound to a solid support via a non-covalent interaction with an analogue of the analyte of interest (the analogue typically being covalently bound to the solid support), the immunoalobulin having a lower affuiity for the analogue than for the analyte. Accordingly.
the presence of the analyte of interest in the sample, even at low concentrations, will tend to cause displacement of the immunoglobulin. Desirably. the binding affinity of the immunoglobulin for the analyte of interest is between 5 and 100 times areater than its affinity for the analogue, typically between 10 and 20 times greater.
For reasons which will become apparent, the method/device of the invention finds particular advantage when applied to the detection of relatively low molecular weight analytes (e.g. steroids and the like) having molecular weights of around RD or less. One such analyte is the steroid estradiol, or metabolites thereof such as estrone-3-2lucuronide.
Thus. for example. where the analyte of interest is estrone-3-alucuronide, a suitable analoeue thereof for use in detecting the presence of the analyte in accordance with the invention may be estriol-3-glucuronide. Other possibly suitable anaiogues will be apparent to those skilled in the art and include. for example, estrone, estrone-3-sulphate, estriol, estradiol and estradiol-3-glucuronide.
In an alternative embodiment, the assay method of the invention may involve displacement not of a binding partner of the analyte, but of an analogue of the analyte.
For example, an immunoglobulin mav be immobilised on a solid support in such a way that at least one antigen binding site is available for binding antigen. Typically, prior to performance of the assav, substantially all of the available binding sites are occupied by an analogue of the analyte of interest, the immunoglobulin having a lower binding affinity for the analogue than for the analvte of interest such that, upon addition of a sample containing the analvte of interest, the analogue will he displaced from the binding site of the immunoglobulin.
The immunoglobulin (e.g. IgM) could have a pluralitv of binding sites such that one binding site interacts with antigen bound to a solid support, leavinQ another free to be occupied bv analvte analogue prior to assav. Alternativelv, the antibody could possess a single binding site (like Fv or Fab fragments of Ig) but be immobilised to a solid support in such a wav that the single binding site is available for occupation.
Immunoglobulin molecules (such as IgG) may conveniently be immobilised via an anti-Fc antibody, as described in Example 2 below.
Thus, in one embodiment, an anti-Fc antibody is immobilised (typically via a covalent interaction) upon a solid support. A second antibody, specific for the analyte of interest, is then captured on the solid support by the anti-Fc antibody. The binding sites of the analyte-specific antibody are then substantially fully occupied by an analogue of the analyte of interest, such that the analogue is reversibly immobilised upon the solid support via non-covalent interaction with the analyte-specific antibody. The affinity of the analyte-specific antibodv for the analyte of interest is desirably between 5 and 100 times greater than its affinity for the analogue.
Conveniently, the solid support comprises part of a biosensor device. A
biosensor may be defined as an analytical device which comprises a biological molecular recognition component, which device typically produces an electronic signal dependent on the presence and/or concentration of an analyte interacting with the biological recognition component.
AMENDED SHEET
Such biosensor devices are well-known and are described, for example, in EP 0 341 927, EP 0 416 730 and EP 0 453 224. Preferably the biosensor detects a change in a mass-dependent property of the solid support (e.g. speed of propagation of an acoustic wave, propagation of an evanescent wave, or surface plasmon resonance). Examples of such devices which utilise the evanescent wave or SPR phenomena (Hutchinson 1995 Molecular Biotechnology 3, 47-54 and references therein) include the BIAIiteTM and BIAcoreTM
devices sold by Biacore AB, the IAsysTM device sold by Affinity Sensors Limited (UK), and the BIOS-1 device sold by Artificial Sensor Instruments (Zurich, Switzerland).
Displacement of antibody molecules from the sensor surfaces of such devices causes a relatively large decrease in mass, which is readily detectable. However, in those embodiments where an analogue of the analyte of interest is displaced by the analyte, it will be apparent to those skilled in the art that, for evanescent wave-type sensors and other mass-dependent biosensors, the analogue must have a sufficientlv hiaher molecular weight than the analyte, otherwise the net change in mass may be very small and thus difficult to detect.
For example, where the analyte is a low molecular weight compound. such as a steroid or a peptide, the analogue may be conjugated to a high molecular weight substance so as to create a higher molecular weiQht difference between the analvte and the analogue. High molecular weiaht substances suitable for conjugation include proteins such as ovalbumin or bovine serum albumin (BSA), or other entities such as lipids and the like.
It is to be noted that these substances are not conventional labels such as enzymes, radiolabels, fluorescent or chemiluminescent tags, redox labels or coloured particles and the like, but serve merely to create a disparity in molecular weiaht between the analyte and the analogue.
Alternatively, where the analogue is a peptide. the molecular weiaht of the analogue may be increased relative to the analyte, by using the peptide as part of a fusion protein.
Conveniently the peptide may be fused to the N-terminal or, more preferably, the C-terminal of a polypeptide. Methods for the construction of DNA sequences encoding such fusion proteins are well known to those skilled in the art.
The added molecular mass represented by the polypeptide may be viewed as a non-conventional label. However, the fused or, as may be the case conjugated, polypeptide need not retain any particular activity unlike, say, an enzyme label, so that the assay component will not become less sensitive due to loss of activitv durinQ
storage. Similarly, the use of a single polypeptide rather than a comparatively larae latex bead (as in the prior art) will introduce comparatively few non-specific binding sites, such that the accuracy of the assav will not be adversely affected.
Brief Description of the Figures Fizure 1 shows the structural formulae of the compounds (I) estrone 3-D-glucuronide (abbreviated as estrone-3-glucuronide or E3G) and (II) estriol 3-(0-D-alucuronide) (abbreviated as estriol-3-aiucuronide), which compounds are utilised in Example 1 below;
Figure 2 is a schematic representation of the assay format described in Example 1 below;
Figure 3 is a sensorgram (arbitary Resonance Units, "RUs". against time measured in seconds) showing the preparation of an estriol-3-~lucuronide sensor chip;
Figure 4 is a(zraph of Resonance Units against time (seconds). showing displacement of 4155 antibodv bv estrone-3-alucuronide:
Figure 5 is a;raph of amount of 4155 antibody displaced (RUs) aQainst concentration of estrone-3-jlucuronide (nM):
Figttre 6 is a schematic representation of the assay format desribed in Example 2 below;
Figure 7 is a sensorgram (arbitary Resonance Units aQainst time, in seconds) showing the preparation of a Rabbit anti-mouse (RAM) Fc sensor chip;
Figure 8 is a sensorgram (Resonance Units against time, in seconds) showing binding of anti-human milk fat globulin HMFG I antibody to a RAM Fc sensor chip, and binding of CPDTR peptide-conjugate to the HMFG1 antibody; and Figure 9 is a sensorgram (Resonance Units against time, in seconds) showing displacement of CPDTR peptide-conjugate from HMFG1 antibody by KPDQR peptide.
Examples Example 1 In this example an assay is described which utilises surface plasmon resonance (SPR).
This phenomenon has now been described in several publications and is the basis of evanescent wave biosensors (for a review, see Hutchinson 1995 cited above).
In summary, lioht incident on an interface between two media of different refractive indices will, at a specific angle of incidence, generate a resonant "evanescent" wave. The resonance is extremely sensitive to chancres in the refractive index of the media. A change in the refractive index causes resonance to occur at a new angle of incidence.
The change in refractive index is caused bv mass binding to a thin gold film at the interface between the two media: the chanQe in refractive index is proportional to the mass bound to the gold film.
This example concerns an assay for the detection of estrone-3-glucuronide (a steroid hormone metabolite) and involves use of an analogue thereof, estriol-3-2lucuronide.
Details of the structures of these compounds are shown in Figure 1.
Further by way of information this example makes use of the Pharmacia BIAIiteTM
evanescent wave biosensor (Jonsson et al., 1991 BioTechniques II, 620-627).
Figure 2 schematicallv illustrates the assay method. In step "A". an analoaue (estriol-3-Qlucuronide, denoted in Figure 2 bv a solid circle) of the analyte of interest (estrone-3-glucuronide denoted bv a solid triangle) was covalently immobilised on the activated dextran-coated surface of a solid support (a sensor chip of the Pharmacia BIAliteTM
biosensor). In step "B", antibodv (monoclona14155, denoted by the Y shape) specific for estrone-3-glucuronide was then allowed to bind to the immobilised analogue.
The antibody has comparatively low binding affinity for the analogue, such that the antibody is relatively loosely held (reversibly immobilised) on the biosensor chip.
Introduction of a sample containing the analyte of interest (for which the antibody has comparatively high binding affinity) will therefore cause the antibody to bind preferentially to the analyte (step "C") rather than to the immobilised analogue, so causing displacement of the antibody from the sensor chip, which displacement can be readily detected by the sensor device.
As a first step, estriol-3-glucuronide was immobilised on a sensor chip in the BIAIiteTM
biosensor. The method of immobilisation was essentially as described by Johnsson et al.
(1995 J. Molec. Recognition 8, 125-131) and by O'Shanessy et al. (1992 Analytical Biochemistry 205, 132-136). In summary, the process was as follows:-A CM5 sensor chip was docked in to the BialiteT" instrument and equilibrated in the HBS
running buffer. The instrument pump flow rate was set to 5 1/min and temperature was maintained at 25 C.
The dextran surface was then activated using the 1-ethyl(dimethvlaminopropyl)carbodiimide (EDC) and N-hvdroxvsuccinimide (NHS) activating chemicals from the Pharmacia amine coupling kit bv injecting the EDC/NHS
mixture into the sample loop and loading 35,ul over the dextran surface.
EDC/NHS
activation can be seen at position (1) on the sensorgram in Figure 3.
After the surface was activated by EDC/NHS 20% (v/v), ethylene diamine (EDA) (Fluka, Code 03550) in water was injected into the sample loop. 35 1 of this solution was loaded over the surface. This changes the surface groups from carboxvl to amine derivatised.
This can be seen at position (2) on the sensorgram in Figure 3.
Estriol-3-Qlucuronide (Sigma. Code E-2002) was dissolved at l.lmg/mi concentration in EDC/NHS activation mixture and left to react for 7 minutes. This solution was then injected into the sarnple loop and 57 1 of this solution was loaded over the dextran/EDA
surface. This can be seen at position (3) on the sensorgram in Figure 3.
The sensor chip was then washed with HEPES-buffered saline (HBS).
The assay was performed as follows:-i) The estriol-3-glucuronide sensor chip was docked in the BIAliteT"
instrument and equilibrated with HBS running buffer. The temperature was maintained at 25 C
and pump flow rate kept at 5 l/min.
ii) Mouse monoclonal antibody specific for estrone-3-glucuronide (produced bvi cell line "4155 ") was diluted to 30 g/ml in HBS buffer. This solution was injected into the sample loop and 35 1 was loaded over the biosensor chip surface. The 4155 monoclonal cell line was prepared and screened accordinLy to the methods described by Gani et al.,(1994 J.
Steroid Biochem. Molec. Biol. 48, 277-282). The Gani et al. publication relates to development of anti-progesterone antibodies, but essentially identical techniques were emploved in producing antibodies reacting with estrone and analogues thereof.
Antibodies other than that obtainable from cell line 4155 may readily be produced by those skilled in the art (using such techniques): such antibodies would have qualitativelv similar properties.
Moreover, a commerciallv available anti-estrone alucuronide monoclonal antibody (from Wallaceville Animal Research Centre. New Zealand) is described in Linscott's Directory of Immunological and Bioloaical Reagents (9th edition, 1996-7).
iii) Estrone-3-alucuronide (Sigma product code E1752) was dissolved in HBS
buffer at 1mg/ml. This was diluted further to 20.5nM, 2.05nM and 0.205nM concentrations with HBS buffer respectively. The concenrations used represent the physiological concentrations of E3G found in urine (Stancyzk et al., 1930 Am. J. Obs. &
Gynae.
137(4), 443-450). The 20.5nM E3G solution was injected into the sample loop and 35 i was loaded over the biosensor chip surface to displace the bound 4155 antibody.
iv) After the injection was complete the remaining antibodv was removed usina a 1041 loadin2 of 100mM HCl over the biosensor chip surface.
v) Steps (ii) to (iv) were repeated using the estrone-3-glucuronide dilutions at 2.05nM
and 0.205nM respectively.
Preparation of sensor chip The sensorgram for the immobilisation of the sensor chip is shown in Figure 3.
The steroid coupled to the surface cannot be detected by looking at the sensorgram trace and comparing the baseline before immobilisation and after immobilisation. This is because the estriol-3--lucuronide molecular weight is below the limit of detection for the BIAIiteTM.
Investi2ation of the displacement reaction with the estriol-3-alucuronide sensor chip The 4155 antibodv was able to bind in large amounts to the estriol-3-glucuronide that had been covalently linked to the sensor chip. The 4155 antibody was displaced from the surface of the chip upon injection of the estrone-3-glucuronide. The amount of antibody displaced by the estrone-3-glucuronide was dependant on the steroid concentration (see Figure 4: the solid line shows results using 0.2nM E3G, the dashed line shows results obtained with 2.OnM E3G, the dashed line shows results obtained with 2.0nM
E3G, and the dotted line shows results obtained with 2.OnM E3G, and the dotted line shows results obtained using 20nM E3G). To show this was a linear correlation a graph (Figure 5) was drawn plotting steroid concentration against (i) the amount of antibody displaced in RUs (left hand vertical axis) and (ii) the % of antibody displaced compared to the amount bound to the surface (right hand vertical axis).
The concentrations of estrone-3-glucuronide (E3G) used in the experiment span the physiological range of E3G concentrations found in human urine samples. In the displacement experiment, it is clearly seen that the amount of antibody displaced by the E3G steroid is directly proportional to the concentration of the E3G (see Figure 5).
This displacement reaction demonstrates the possibility of ineasuring small molecular liaands with the biosensor that themselves are below the minimum threshold for detection by surface plasmon resonance with the BIAIiteTM instrument. The displacement reaction can form the basis of new immunoassay formats that requires no labelling of reagents with enzymes or radioactive molecules. All that is required for this type of assay to work is a low affinity antigen analogue that can be immobilised to the dextran.
Example 2 Displacement of crossreactive svnthetic peptide ovalbumin conjuQates from antibody A schematic illustration of this displacement reaction can be seen in Figure 6.
Referring to Figure 6, the solid support is the sensor chip of the Pharmacia BIA1iteTM
biosensor, coated with activated dextran. A first antibody (polyclonal rabbit anti-mouse immunogiobulin G["RAM"] specific for the Fc portion of IgG), was covalently immobilised to the activated dextran ("A"). Next, a second (mouse) antibody, specific for the analyte of interest, is added ("B"). The analvte of interest in this example is a peptide (KPDQR) derived from human milk fat globulin (HMFG)1 protein. The anti-HMFG1 monoclonal antibody is described by Taylor-Papadimitriou et al (1981 Int. J.
Cancer 28, 17). The anti-HMFG1 monoclonal antibody is captured on the sensor chip by the RAM
first antibodv. The first and second antibody molecules are shown in FiQure bv the Y
shapes.
Next an analogue (peptide CPDTR using the single letter amino acid code) of the peptide analyte of interest was introduced. In this example, both the analyte and the analogue are low molecular weight peptides, which cannot readily be distinguished by differences in molecular weight. Accordingly, a high molecular weight polypeptide (ovalbumin) was chemically conjugated to the peptide analogue. This peptide-ovalbumin conjuoate (shown in Figure 6 as a solid oval shape) was bound with relatively low affinity by the anti-HMFG1 antibody, such that the analogue was reversibly immobilised on the solid support (C). When the peptide analyte of interest (KPDQR, shown in Figure 6 as a solid triangle) was introduced, the anti-HMFG1 tended to bind preferentially thereto (having a higher affinity for the analyte of interest than for the analogue). Accordingly ("D") the analyte became bound to the sensor chip and the higher molecular weight analogue -ovalbumin conjugate was displaced. The change in mass bound to the sensor chip can be detected by the BIAIite" device.
a) Preparation of polvclonal rabbit anti-mouse immunoQlobulin G (Fc specific) sensor chin i) A carboxy methyl dextran (CM5) sensor chip (Pharmacia. Code BR-1000-14) was docked in to the BIA1iteT't instrument and equilibrated in the HEPES buffered saline (HBS) (Pharmacia, Code BR-1001-88). The instrument pump flow rate was set to 5 l/min and temperature was maintained at 25 C.
ii) The dextran surface was then activated using the EDC and NHS activatinsz chemicals from the amine coupling kit (Pharmacia, Code BR-1000-50). EDC/NHS mixture was injected into the sample loop and 35 1 of this solution loaded over the dextran surface.
EDC/NHS activation can be seen at position (1) on the sensorgram in Figure 7.
iii) Polvclonal rabbit anti-mouse immunoglobulin G (Fc specific) (RAM Fc) (Pharmacia.
code BR-1000-57) was diluted down to 50 g/ml in 10mM acetate buffer pH5.0 and injected into the sample loop. 35 1 of this solution was loaded over the dextran surface.
The coupling of the RAM Fc to the dextran can be seen at position (2) on the sensorgram in Figure 7.
iv) Once the RAM Fc loading was complete and unbound RAM Fc washed from the dextran surface by HBS running buffer, the remaining activated ester sites on the dextran surface were reacted with ethanolamine. 1M ethanolamine pH8.5 (Pharmacia amine coupling kit. Code BR-1000-50) was injected in to the sample loop and 3541 loaded over the dextran/RAIVI Fc surface. This can be seen at position (3) on the sensorgram in Figure 7.
v) To remove any non-covalentlv attached RA..M Fc from the surface 100mM HCI
was injected in to the sample loop and lOul of this solution was loaded over the dextran/RA.M
Fc surface. This can be seen at position (4) on the sensorgram in Figure 7.
b) Preparation ot svnthetic peptides Cvs-Pro-Asp-Thr-Ara (CPDTR) and Lvs-Pro-As]2-Gln-Aro (hPDOR) for the displacement reaction The peptides used here were modified variants of the natural epitope Pro-Asp-Thr-Arg (PDTR) sequence in the human milk fat globulin 1 protein to which the antibody anti-HMFG1 binds (Bri(y,s et al., 1991 Immunology 73, 505-507). The Cys (C) in CPDTR
was added to allow the peptide to be coupled to commercially available maleimide activated ovalbumin and create a useful conjugate. This conjugate is required since the peptide alone does not have sufficient mass to be detected by the BIAIiteTM
instrument.
There is a threshold of about 5000 daltons of mass required before molecules will register with the BIAlite" instrument.
Whilst the work described in this example relates to experiments performed with the monoclonal antibody HMFG1, other antibodies having qualitatively similar properties may readily be produced by those skilled in the art. Moreover, a commercially available anti-milk fat globulin monoclonal antibody (from Paesel & Lorei GmbH, Hanau.
Germany) is described in Linscott's Directorv of Immunological and Biological Reagents (9th edition, 1996-7).
In the work done to identify the critical aminoacid residues within the HMFGI
epitope (Price et al., 1991 J. Immunological Methods 139, 83-90) a number of variants were created that had affinities differine from the native PDTR sequence. Pro-Asp-Gln-Arg (PDQR) is an analogue of the PDTR sequence that has a higher affinitv for the antibody than PDTR. The peptide KPDQR was synthesised with an N-terminal lysine to improve the soluhility of the peptide. However, as this peptide contained the PDQR
sequence it was also suitable for investigating the immunodisplacement reaction. The N-terminal lysine could be readily omitted without substantial deleterious effect.
AMENDED SHEET
i) Peptides were synthesised on a Novabiochem GEM semi-automatic synthesizer, using standard techniques as previously published (Merrifield, 1963 J. Am. Chem.
Soc. 85, 2149-2154). Briefly, Fmoc-aminoacid reagents (Novabiochem) were activated sequentially using PyBOP chemistry (Grant, 1992 "Synthetic peptides. A user's guide" pub. W
H
Freeman & Co New York). These activated aminoacids were coupled to the solid support Novasyn TGR resin (0.8g) (Novabiochem) to produce the protected peptide attached to a solid matrix. Dimethylformamide (DMF) solvent was used throughout the synthesis. The peptides were reacted with acetic anhydride (10% in DMF) to block the N-tetmini.
ii) The peptide was then deprotected and cleaved using standard cleavage conditions with 20m1 of cleavage solution per peptide [92.5 % (v/v) Trifluoroacetic acid (TFA) (Aldrich), 2.5% (v/v) Ethanedithiol (Aldrich). 2.5 %(v/v) water, 2.5 %(v/v) triisopropylsilane (Aldrich)]. The solution was filtered to remove the resin and rotary evaporated under vacuum at 30 C with cold finger (dry ice/acetone) trap to remove all excess solvents.
This procedure took 30 minutes.
iii) Residual chemical contaminants were removed by precipitating the peptide with diethyl ether (Aldrich) and repeated extraction of this precipitate with excess diethyl ether.
iv) The peptide precipitate was then solubilised with water and freeze dried.
The resultin2 powder was stored at -20 C until required.
c) Preparation of the CPDTR peptide ovalbumin conjugate Peptide was dissolved in phosphate buffered saline (PBS) to a concentration of 5mg/ml and mixed with 5 milligrams of preactivated maleimide ovalbumin (Pierce) dissolved in lml of PBS. This mixture was left to react at room temperature for 2.5 hours. The excess peptide was then removed by dialysing the sample against 5L of PBS + 0.1 %
sodium azide (Sigma,) for 16 hours at 4 C.
The conjugate was then removed from dialysis and stored at 4 C until required.
d) Displacement of the CPDTR pentide-ovalbumin coniueate from monoclonal HMFGl antibodv with KPDOR peptide The polyclonal rabbit anti-mouse antibody (Fc specific) biosensor chip was placed into the BIAIiteTM instrument and the docking procedure executed. The HEPES buffered saline (HBS) running buffer (Pharmacia product code BR-1001-88) flow rate was then set at 1/min.
A typical sensorgram for the preparation of the RAM Fc sensor chip is shown in Figure 7. Referring to Figure 7. 1 represents the EDC/NHS activation of the dextran surface, 2 represents the RAM Fc coupling to the activated dextran, 3 represents blocking of residual activated dextran sites with ethanolamine, and 4 represents a 100mM
HCI pulse to remove non-covalently bound substances.
Mouse monoclonal antibody specific for human milk fat globulin 1 was diluted to 50)cg/ml in HBS buffer and 35 1 of this solution was injected in to the biosensor chip.
After injection the biosensor chip was automatically washed and 1040 RU of the mouse specific antibody had been bound by the polyclonal rabbit anti-mouse antibody (Fc specific) antibody.
The CPDTR-ovalbumin conjugate was diluted tenfold with HBS buffer and 351A1 of this solution was injected into the biosensor chip. Approximately 204 resonance units were bound by the mouse HMFG1 specific antibody. Peptide KPDQR was dissolved to 200 g/ml in HBS buffer and 35 1 of this solution was injected into the biosensor chip to displace the CPDTR-ovalbumin conjugate.
The residual bound CPDTR-peptide conjugate and mouse anti-HMFG1 were then removed by washing the sensor chip briefly with 100mM HCI.
A control experiment was performed in an identical manner except no peptide Lys-Pro-Asp-Gln-Arg was injected.
Results Preparation of RAM Fc sensor chip The coupling of the sensor chip resulted in a high capacity RAM Fc specific sensor chip that had approx 8000 RU of RAM Fc immobilised at the end of the procedure (see Figure 7). The RAM Fc binds the mouse HMFG1 antibody with multiple binding sites for each antibody molecule, thus giving a high avidity for the molecule. The effect of the high avidity is negligible dissociation of the monoclonal antibody from the RAM Fc layer.
This can be seen at position 2 in Figure 8 where there is almost a flat line for the dissociation of HMFG1 from RAM Fc. This condition is required in order to ensure that any loss of RUs in the displacement experiment is due to immunospecific displacement of CPDTR-ovalbumin by the KPDQR peptide, and not the HMFGI monoclonal antibody dissociating from the RAM Fc layer.
In Figure 8, (1) represents HMFG1 binding to the RAM Fc sensor chip, (2) represents dissociation of HMFG1 antibody from RAM Fc layer, (3) represents CPDTR-ovalbumin conjugate binding to HMFG1 antibody, and (4) represents dissociation of CPDTR-ovalbumin conjugate from HMFG1 antibody.
The SPR signal from molecular binding events is reduced by the mass of the molecule and the distance the event occurs from the resonating gold layer. Molecular interaction studies that require several layers of molecules to be assembled have to compensate for the reductions in signals that occur as each layer of molecules is added and the distance from the gold layer increased. Compensating for this problem is achieved by inunobilising large amounts of ligand in the first layer of the test system. This overcomes the signal reductions and the final molecular binding events are easily observed.
The RAM Fc sensor chip was capable of binding 1000 RU of mouse monoclonal HMFGI
antibody. This was sufficient to ensure that binding of the CPDTR-ovalbumin peptide conjugate to HMFG1 antibody and any displacement effect by peptide KPDQR on the CPDTR-ovalbumin conjugate bound to HMFG1 antibody would be easily observed (see Figure 8).
Displacement of CPDTR-ovalbumin coniuQate from HMFG1 antibodv bv peptide KPDOR
In order to observe whether there had been any displacement of the CPDTR-ovalbumin by the peptide KPDQR, the raw data were analysed in the BIAevaluation package.
Essentially, the two regions of data for the binding of CPDTR-ovalbumin conjugate to HMFG1 antibody with and without the following peptide displacement were plotted as separate graphs and overlaid. To keep the data synchronised the graphs were both aligned at the point of injection for the CPDTR-ovalbumin conjugate (see Figure 9).
The curve with no peptide injected (solid line in Figure 9) shows the normal dissociation of the CPDTR-ovalbumin conjugate from the HMFGI antibody. This is essentially the baseline from which the immunospecific displacement is measured.
The curve with peptide added (broken line in Figure 9) shows the immunodisplacement.
Immediately after the peptide KPDQR injection (denoted by a downward vertical arrow in the Figure) starts there is a sharp rise in the resonance unit signal. This is due to the change from instrument HBS running buffer to the KPDQR peptide buffer and is called "bulk refractive index change".(Bulk refractive index changes occur when samples with buffer composition different from the HBS running buffer of the instrument are injected over the sensor chip. The difference in the ionic strength of the HBS and sample buffers results in a change in the refractive index where the evanescent wave is probing the dextran layer. The refractive index change gives an immediate shift in resonance signal which is observed on the sensorgram.) This increase in resonance units caused by the bulk refractive index change is rapidly lost because immunodisplacement of the CPDTR-ovalbumin conjugate from the HMFG1 antibodv is occurrina, and the loss of mass due to this displacement causes a drop in the resonance signal. Eventually the signal curve flattens because the peptide has removed all the CPDTR-ovalbumin conjugate possible and all that remains is multiply bound CPTDR-ovalbumin conjugate which has such high avidity that it cannot be displaced. At the end of the peptide injection there is an immediate drop in the resonance unit signal that is caused by the switch from sample buffer to the HBS instrument running buffer. A
comparison of the curves with and without peptide injected, i.e.
immunodisplacement versus normal dissociation. shows that there is an additional loss of 100 RU
of CPDTR-ovalbumin conjugate from the HMFG 1 antibody caused by the KPDQR peptide (indicated by the double-headed vertical arrow in Figure 9).
From the data presented in these examples one can see how the invention can be used with particular advantage to assay low molecular weight analytes, such as steroids or peptides, without the need to label any of the assay components.
Claims (11)
1. A method of detecting the presence of an analyte of interest in a sample, the method comprising the steps of: contacting the sample with a solid support having reversibly immobilised thereon either a binding partner having specific binding affinity for the analyte, or an analogue of the analyte; wherein the binding affinity of an interaction by which the binding partner or analogue are reversibly immobilised on the solid support is lower than the binding affinity of the binding partner for the analyte of interest or the binding affinity of the solid support for the analyte of interest, respectively, such that said binding partner or analogue is specifically displaced from the solid support in the presence of the analyte of interest, so as to cause a detectable reduction in the mass of material immobilised thereon; and detecting a reduction in the mass of material immobilised on the solid support, said reduction indicating the presence of an analyte of interest, wherein the solid support comprises part of an evanescent wave, acoustic wave or surface plasmon resonance (SPR) sensor device.
2. A method according to claim 1, wherein the reversibly immobilised binding partner is an immunoglobulin or a functional binding fragment thereof.
3. A method according to claim 1 or 2, wherein the reversibly immobilised binding partner is a bispecific antibody.
4. A method according to any one of claims 1, 2 or 3, wherein the reversibly immobilised binding partner is immobilised on the solid support by interaction with an analogue of the analyte of interest, the binding partner having lower binding affinity for the analogue than for the analyte of interest.
5. A method according to claim 1, wherein the analogue of the analyte of interest is reversibly immobilised on the solid support by interaction with an immunoglobulin or a functional binding fragment thereof, said immunoglobulin or functional binding fragment thereof having lower binding affinity for the analogue than for the analyte of interest.
6. A method according to any one of claims 1 to 5, wherein the solid support comprises part of a biosensor device.
7. A method according to any one of claims 1 to 6, wherein the analyte of interest is estradiol, or a metabolite thereof.
8. A method according to any one of claims 1 to 7, wherein the analyte of interest is estrone-3-glucuronide or estriol-3-glucuronide.
9. A method according to any one of claims 1 to 8, wherein the reduction in the mass of material immobilized on the solid support is detected by a change in the refractive index at the surface of the support.
10. An assay device for detecting the presence of an analyte of interest in a sample, the device comprising: a solid support having reversibly immobilized thereon either a binding partner having specific binding affinity for the analyte, or an analogue of the analyte; wherein the binding affinity of an interaction by which the binding partner or analogue are reversibly immobilized on the solid support is lower than the binding affinity of the binding partner for the analyte of interest or the binding affinity of the solid support for the analyte of interest, respectively, such that the presence of the analyte of interest in the sample causes specific displacement of the binding partner or analogue from the solid support, so as to cause a detectable reduction in the mass of material immobilized thereon; and detection means for detecting a reduction in the mass of material immobilized on the solid support, wherein the solid support comprises part of an evanescent wave, acoustic wave or surface plasmon resonance (SPR) sensor device.
11. A device according to claim 10, for use in performing the method of any one of claims 1-9.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96303693.4 | 1996-05-23 | ||
| EP96303693 | 1996-05-23 | ||
| PCT/EP1997/002694 WO1997044664A1 (en) | 1996-05-23 | 1997-05-20 | Improvements in or relating to specific binding assays |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2254108A1 CA2254108A1 (en) | 1997-11-27 |
| CA2254108C true CA2254108C (en) | 2008-07-22 |
Family
ID=8224952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002254108A Expired - Lifetime CA2254108C (en) | 1996-05-23 | 1997-05-20 | Improvements in or relating to specific binding assays |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6294391B1 (en) |
| EP (1) | EP0901630B1 (en) |
| JP (1) | JP2000503773A (en) |
| AT (1) | ATE247830T1 (en) |
| AU (1) | AU2961397A (en) |
| CA (1) | CA2254108C (en) |
| DE (1) | DE69724249T2 (en) |
| WO (1) | WO1997044664A1 (en) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| JP4220124B2 (en) * | 1997-11-21 | 2009-02-04 | インバーネス・メデイカル・スウイツツアーランド・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | Improvements in displacement assays or improvements in displacement assays |
| EP1090296A1 (en) * | 1998-06-26 | 2001-04-11 | Moorlodge Biotech Ventures Limited | Analyte assay device |
| AU2103600A (en) * | 1999-01-25 | 2000-08-07 | Unilever Plc | Improvements in or relating to displacement assays |
| GB9922352D0 (en) * | 1999-09-21 | 1999-11-24 | Avidex Ltd | Screening method |
| ATE335202T1 (en) | 2000-03-16 | 2006-08-15 | Biacore Ab | METHOD FOR COLLECTION OF ANALYTES ELUTED FROM SURFACE BONDED LIGANDS |
| US7297354B2 (en) | 2000-04-26 | 2007-11-20 | Land O'lakes, Inc. | Protein material |
| CA2418131A1 (en) * | 2000-08-03 | 2002-02-14 | Inverness Medical Switzerland Gmbh | Peptides capable of functioning as mimotopes for estradiol analytes |
| US6576430B1 (en) * | 2000-11-20 | 2003-06-10 | Becton, Dickinson And Company | Detection of ligands by refractive surface methods |
| CA2460212C (en) | 2001-09-06 | 2013-01-22 | Genomic Profiling Systems, Inc. | Rapid and sensitive detection of cells and viruses |
| US6713272B2 (en) * | 2001-09-19 | 2004-03-30 | The United States Of America As Represented By The Secretary Of The Navy | Attachment of biomolecules to hydrophobic surfaces |
| US20030119203A1 (en) | 2001-12-24 | 2003-06-26 | Kimberly-Clark Worldwide, Inc. | Lateral flow assay devices and methods for conducting assays |
| US6837171B1 (en) | 2002-04-29 | 2005-01-04 | Palmer/Snyder Furniture Company | Lightweight table with unitized table top |
| KR100467315B1 (en) * | 2001-12-26 | 2005-01-24 | 한국전자통신연구원 | Biosensor using competitive binding, and kit and method for detecting glucose using the same |
| US20030186464A1 (en) * | 2002-01-29 | 2003-10-02 | Michelle Arkin | Surface plasmon resonance methods |
| CN100412548C (en) * | 2002-06-19 | 2008-08-20 | 瑞典生物传感器应用股份公司 | Coated metal surface on solid support useful in analyte detection by displacement |
| US7285424B2 (en) | 2002-08-27 | 2007-10-23 | Kimberly-Clark Worldwide, Inc. | Membrane-based assay devices |
| US9701754B1 (en) | 2002-10-23 | 2017-07-11 | City Of Hope | Covalent disulfide-linked diabodies and uses thereof |
| JP2004170195A (en) * | 2002-11-19 | 2004-06-17 | Reverse Proteomics Research Institute Co Ltd | Protein immobilization method |
| US7781172B2 (en) | 2003-11-21 | 2010-08-24 | Kimberly-Clark Worldwide, Inc. | Method for extending the dynamic detection range of assay devices |
| CN1902491A (en) * | 2003-11-20 | 2007-01-24 | 瑞典生物传感器应用股份公司 | Mixture of at least two different antibodies specific for predetermined antigens and use of the mixture |
| US7713748B2 (en) | 2003-11-21 | 2010-05-11 | Kimberly-Clark Worldwide, Inc. | Method of reducing the sensitivity of assay devices |
| US7943395B2 (en) | 2003-11-21 | 2011-05-17 | Kimberly-Clark Worldwide, Inc. | Extension of the dynamic detection range of assay devices |
| US20050191704A1 (en) * | 2004-03-01 | 2005-09-01 | Kimberly-Clark Worldwide, Inc. | Assay devices utilizing chemichromic dyes |
| JP2005283296A (en) * | 2004-03-29 | 2005-10-13 | Takatoshi Kinoshita | Optical detection method of specimen, and detection system |
| JP2008513772A (en) * | 2004-09-15 | 2008-05-01 | エイジェンシー フォー サイエンス， テクノロジー アンド リサーチ | Surface plasmon resonance and quartz crystal microbalance sensor |
| DE102004062012A1 (en) | 2004-12-23 | 2006-07-20 | Robert Bosch Gmbh | Method for operating a hybrid vehicle |
| US7939342B2 (en) | 2005-03-30 | 2011-05-10 | Kimberly-Clark Worldwide, Inc. | Diagnostic test kits employing an internal calibration system |
| US7858384B2 (en) | 2005-04-29 | 2010-12-28 | Kimberly-Clark Worldwide, Inc. | Flow control technique for assay devices |
| US7439079B2 (en) | 2005-04-29 | 2008-10-21 | Kimberly-Clark Worldwide, Inc. | Assay devices having detection capabilities within the hook effect region |
| US7803319B2 (en) | 2005-04-29 | 2010-09-28 | Kimberly-Clark Worldwide, Inc. | Metering technique for lateral flow assay devices |
| US7504235B2 (en) * | 2005-08-31 | 2009-03-17 | Kimberly-Clark Worldwide, Inc. | Enzyme detection technique |
| US7829347B2 (en) * | 2005-08-31 | 2010-11-09 | Kimberly-Clark Worldwide, Inc. | Diagnostic test kits with improved detection accuracy |
| US8003399B2 (en) * | 2005-08-31 | 2011-08-23 | Kimberly-Clark Worldwide, Inc. | Nitrite detection technique |
| WO2007038478A2 (en) | 2005-09-26 | 2007-04-05 | Rapid Micro Biosystems, Inc | Cassette containing growth medium |
| US7279136B2 (en) | 2005-12-13 | 2007-10-09 | Takeuchi James M | Metering technique for lateral flow assay devices |
| US7618810B2 (en) * | 2005-12-14 | 2009-11-17 | Kimberly-Clark Worldwide, Inc. | Metering strip and method for lateral flow assay devices |
| US7794656B2 (en) | 2006-01-23 | 2010-09-14 | Quidel Corporation | Device for handling and analysis of a biological sample |
| US7871568B2 (en) | 2006-01-23 | 2011-01-18 | Quidel Corporation | Rapid test apparatus |
| EP2650306A1 (en) | 2006-03-06 | 2013-10-16 | Aeres Biomedical Limited | Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| JP2009531324A (en) | 2006-03-20 | 2009-09-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Engineered anti-prostatic stem cell antigen (PSCA) antibody for cancer targeting |
| US20080057528A1 (en) * | 2006-08-30 | 2008-03-06 | Kimberly-Clark Worldwide, Inc. | Detection of hydrogen peroxide released by enzyme-catalyzed oxidation of an analyte |
| EP2102659B1 (en) * | 2006-12-13 | 2012-10-31 | Biosensor Applications Sweden AB (Publ) | Continuously repeatable method of detecting antigens in test volume |
| CN101595387B (en) * | 2006-12-13 | 2014-01-29 | 生物传感器应用国际有限公司 | Continuously repeatable method of detecting antigens in test volume |
| US8012761B2 (en) * | 2006-12-14 | 2011-09-06 | Kimberly-Clark Worldwide, Inc. | Detection of formaldehyde in urine samples |
| US7846383B2 (en) * | 2006-12-15 | 2010-12-07 | Kimberly-Clark Worldwide, Inc. | Lateral flow assay device and absorbent article containing same |
| US7935538B2 (en) | 2006-12-15 | 2011-05-03 | Kimberly-Clark Worldwide, Inc. | Indicator immobilization on assay devices |
| US8377379B2 (en) * | 2006-12-15 | 2013-02-19 | Kimberly-Clark Worldwide, Inc. | Lateral flow assay device |
| EP2703011A3 (en) | 2007-05-07 | 2014-03-26 | MedImmune, LLC | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| CA2698343C (en) | 2007-09-04 | 2018-06-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
| US11865534B2 (en) | 2008-09-24 | 2024-01-09 | First Light Diagnostics, Inc. | Imaging analyzer for testing analytes |
| EP2358392B1 (en) | 2008-11-12 | 2019-01-09 | MedImmune, LLC | Antibody formulation |
| EP2398504B1 (en) | 2009-02-17 | 2018-11-28 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
| CA3040276A1 (en) | 2009-12-02 | 2011-06-09 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
| WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
| JP5871500B2 (en) * | 2011-06-20 | 2016-03-01 | 公益財団法人先端医療振興財団 | α-Klotho / FGF23 complex formation inhibiting compound |
| PL2776550T3 (en) | 2011-11-07 | 2018-05-30 | Rapid Micro Biosystems, Inc. | Cassette for sterility testing |
| US9632026B2 (en) * | 2012-01-23 | 2017-04-25 | Flir Systems, Inc. | Optical biosensor referencing method |
| WO2013147217A1 (en) * | 2012-03-30 | 2013-10-03 | 国立大学法人九州大学 | Sensor, detection method, detection system, and detection device |
| EP4060016A1 (en) | 2012-04-16 | 2022-09-21 | Rapid Micro Biosystems, Inc. | Cell culturing device |
| WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
| SG11201602522VA (en) | 2013-10-02 | 2016-04-28 | Medimmune Llc | Neutralizing anti-influenza a antibodies and uses thereof |
| DK3303384T3 (en) | 2015-06-01 | 2021-10-18 | Medimmune Llc | NEUTRALIZING ANTI-INFLUENZA BINDING MOLECULES AND USES THEREOF |
| CA2994951A1 (en) | 2015-08-07 | 2017-02-16 | Imaginab, Inc. | Antigen binding constructs to target molecules |
| DE102015226490A1 (en) * | 2015-12-22 | 2017-06-22 | Universität Leipzig | Procedure for in ovo gender determination of chicks |
| US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
| WO2022153212A1 (en) | 2021-01-13 | 2022-07-21 | Axon Neuroscience Se | Antibodies neutralizing sars-cov-2 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE54109B1 (en) * | 1982-02-10 | 1989-06-21 | Boots Celltech Diagnostics | Assay |
| DE3887771C5 (en) * | 1987-04-27 | 2009-06-04 | Inverness Medical Switzerland Gmbh | Immunoassays and devices therefor. |
| DE68907519T2 (en) * | 1988-05-10 | 1993-10-21 | Amersham Int Plc | Biosensors. |
| US5306644A (en) * | 1988-09-29 | 1994-04-26 | Hewlett-Packard Company | Mass sensor method for measuring analytes in a sample |
| GB8906776D0 (en) * | 1989-03-23 | 1989-05-10 | Amersham Int Plc | Assay method using surface plasmon resonance spectrometry |
| DE69027077T2 (en) * | 1989-09-08 | 1996-10-02 | Hewlett Packard Co | Production of a solid phase, suitable for specific binding of chemical substances |
| US5179028A (en) * | 1990-04-20 | 1993-01-12 | Hughes Aircraft Company | Antibody coated crystal chemical sensor |
| US5229301A (en) * | 1991-06-07 | 1993-07-20 | Hewlett-Packard Company | Mass biosensor method with quantified sensor renewal |
| SE9200917D0 (en) * | 1991-08-20 | 1992-03-25 | Pharmacia Biosensor Ab | ASSAY METHOD |
| WO1993025910A1 (en) * | 1992-06-05 | 1993-12-23 | Pharmacia Biosensor Ab | Assay for multiple analytes with co-immobilized ligands |
| SE9201984D0 (en) * | 1992-06-29 | 1992-06-29 | Pharmacia Biosensor Ab | IMPROVEMENT IN OPTICAL ASSAYS |
| US5354654A (en) * | 1993-07-16 | 1994-10-11 | The United States Of America As Represented By The Secretary Of The Navy | Lyophilized ligand-receptor complexes for assays and sensors |
| IL114692A (en) * | 1995-07-21 | 1999-10-28 | Yissum Res Dev Co | Determination of an analyte in a liquid medium |
-
1997
- 1997-05-20 AU AU29613/97A patent/AU2961397A/en not_active Abandoned
- 1997-05-20 CA CA002254108A patent/CA2254108C/en not_active Expired - Lifetime
- 1997-05-20 AT AT97924008T patent/ATE247830T1/en not_active IP Right Cessation
- 1997-05-20 EP EP97924008A patent/EP0901630B1/en not_active Expired - Lifetime
- 1997-05-20 JP JP9541582A patent/JP2000503773A/en active Pending
- 1997-05-20 WO PCT/EP1997/002694 patent/WO1997044664A1/en active IP Right Grant
- 1997-05-20 DE DE69724249T patent/DE69724249T2/en not_active Expired - Lifetime
- 1997-05-22 US US08/861,693 patent/US6294391B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ATE247830T1 (en) | 2003-09-15 |
| JP2000503773A (en) | 2000-03-28 |
| EP0901630A1 (en) | 1999-03-17 |
| DE69724249T2 (en) | 2004-06-09 |
| US6294391B1 (en) | 2001-09-25 |
| AU2961397A (en) | 1997-12-09 |
| WO1997044664A1 (en) | 1997-11-27 |
| CA2254108A1 (en) | 1997-11-27 |
| EP0901630B1 (en) | 2003-08-20 |
| DE69724249D1 (en) | 2003-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2254108C (en) | Improvements in or relating to specific binding assays | |
| Gizeli et al. | Immunosensors | |
| US5716854A (en) | Solid phase binding assay | |
| JP6678792B2 (en) | Methods for detecting binding partners of multispecific binders | |
| Leatherbarrow et al. | Analysis of molecular recognition using optical biosensors | |
| Quinn et al. | The use of regenerable, affinity ligand-based surfaces for immunosensor applications | |
| JP2002516393A (en) | Kit with ligand binding assay and inhibitory analyte separation region | |
| JP4176826B2 (en) | Aggregation inhibition measurement method and aggregation inhibition measurement reagent | |
| JPH08502586A (en) | Methods to prevent unwanted binding in solid phase assays | |
| KR20120017884A (en) | Development of lateral flow assay using protein g coated magnetic bead and immunochromomatograpic strip and immunochromomatograpic kit | |
| EP0500611B1 (en) | Analytical device and methods | |
| JP3515101B2 (en) | Method for evaluating binding activity between ligand and ligand binding protein | |
| JP3644780B2 (en) | Immunological quantification equipment | |
| JPH1090271A (en) | Immunity measuring method and device utilizing surface plasmon resonance phenomenon | |
| JP4783872B2 (en) | Immunoassay method | |
| CA2309599C (en) | Improvements in or relating to displacement assays | |
| Yu et al. | Real-time analysis of immunogen complex reaction kinetics using surface plasmon resonance | |
| WO2005036171A1 (en) | Method and system for detection of a target analyte | |
| JP3098970B2 (en) | Peptide elution immunoassay for protein | |
| Legay et al. | Bio-analytical Applications of BIAcore, an Optical Biosensor | |
| WO2000043785A1 (en) | Improvements in or relating to displacement assays | |
| Lin et al. | Direct detection of C-reactive proteins in human serum using nanoparticle-enhanced surface plasmon resonance biosensing | |
| JPS60138462A (en) | Quantitative determination of antigen using antigen column |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20170523 |